Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. He currently serves as President and Founder of Aegea Biotechnologies as well as Sr. VP of R&D, and CSO at Biocept. Dr. Arnold has held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, Oasis Biosciences (co-founder), and Gen-Probe (now Hologic). Dr. Arnold is an inventor or co-inventor on 54 issued U.S. patents and more than 200 issued and pending patents worldwide. He is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies core to Hologic assays that generate more than $700M in product revenue annually. Dr. Arnold received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Dr. Sung is a life Science/biotech executive with 25 years of experience in both operating and venture capital roles. Dr. Sung has been a "C-level" executive (CEO/CBO) at multiple life science companies, including ImmunoActiva, Tauriga Sciences, Avita Medical, PliCare Therapeutics and Cylene Pharmaceuticals. Dr. Sung has negotiated numerous transactions, agreements, and partnerships, and she has structured and led financings. She also has built companies as a venture investor. Dr. Sung has a successful track record as a General Partner or Managing Director at several venture firms, including Oxford Bioscience Partners, Coastview Capital and Pearl St. Venture Fund, where her experience also includes ten Board of Directors positions, including five as Chairperson of the Board. Dr. Sung received her Ph.D. in chemistry from Harvard University, where she was a National Science Foundation Pre-Doctoral Fellow, and her B.S. in chemistry from The Ohio State University, Phi Beta Kappa.
Dr. Nelson is a PhD scientist with 32 years experience in the FDA-regulated Molecular Diagnostics industry. Expert in Next Generation Sequencing, including in-house experience with Illumina, Ion Torrent & Pacific Biosciences platforms and associated workflows. Proven track record in innovation and core technology conception, reduction to practice and implementation (co-invented and played a key role in commercialization of multiple technologies, many of which are core to Gen-Probe products that generate >$700MM annual revenue) and broad expertise and experience in intellectual property protection. Ph.D. from UCSD and BS (Chemistry) from California Institute of Technology.